Cost‐Effectiveness of Radiofrequency Renal Denervation in Taiwan Based on Clinical Evidence and Regional Event Rates

ABSTRACT Radiofrequency renal denervation (RF RDN) is recognized as an adjunct therapy for hypertension. This study evaluated the cost‐effectiveness of RF RDN for the Taiwanese healthcare system using results from the SPYRAL HTN‐ON MED randomized, sham‐controlled trial. A decision‐analytic Markov mo...

Full description

Saved in:
Bibliographic Details
Main Authors: Hui‐Chun Huang, Khoa N. Cao, Anne M. Ryschon, Kee‐Wong Phay, Tzung‐Dau Wang, Jan B. Pietzsch
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:The Journal of Clinical Hypertension
Subjects:
Online Access:https://doi.org/10.1111/jch.70090
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849253952405635072
author Hui‐Chun Huang
Khoa N. Cao
Anne M. Ryschon
Kee‐Wong Phay
Tzung‐Dau Wang
Jan B. Pietzsch
author_facet Hui‐Chun Huang
Khoa N. Cao
Anne M. Ryschon
Kee‐Wong Phay
Tzung‐Dau Wang
Jan B. Pietzsch
author_sort Hui‐Chun Huang
collection DOAJ
description ABSTRACT Radiofrequency renal denervation (RF RDN) is recognized as an adjunct therapy for hypertension. This study evaluated the cost‐effectiveness of RF RDN for the Taiwanese healthcare system using results from the SPYRAL HTN‐ON MED randomized, sham‐controlled trial. A decision‐analytic Markov model projected clinical events, costs, and quality‐adjusted life‐years (QALYs) for RF RDN versus standard‐of‐care (SoC) in an Asian population context. Clinical event risk reductions from treatment effects on office‐based systolic blood pressure (oSBP) were derived from a meta‐regression study of 47 hypertension trials. SPYRAL HTN‐ON MED demographics and results (oSBP reduction of 4.9 mmHg against sham) were used in the base case analysis. The incremental cost‐effectiveness ratio (ICER) was assessed against a willingness‐to‐pay (WTP) threshold of three million Taiwan dollars (TWD) per QALY gained. Compared to SoC, RF RDN was projected to reduce clinical events, with relative risks of 0.80, 0.88, and 0.74 for stroke, myocardial infarction (MI), and heart failure (HF), respectively. The incremental costs and QALYs were 216 381 TWD and 0.25, respectively, resulting in an ICER of 850 932 TWD per QALY gained. The ICER was cost‐effective across a broad range of uncertainty analyses. Model‐based projections adjusted for East Asian event rates suggest RF RDN may significantly reduce events, making it a cost‐effective intervention in the Taiwanese healthcare system for treating uncontrolled hypertension.
format Article
id doaj-art-e0dbc2b3b08d452482d87fa4c3785820
institution Kabale University
issn 1524-6175
1751-7176
language English
publishDate 2025-06-01
publisher Wiley
record_format Article
series The Journal of Clinical Hypertension
spelling doaj-art-e0dbc2b3b08d452482d87fa4c37858202025-08-20T03:56:10ZengWileyThe Journal of Clinical Hypertension1524-61751751-71762025-06-01276n/an/a10.1111/jch.70090Cost‐Effectiveness of Radiofrequency Renal Denervation in Taiwan Based on Clinical Evidence and Regional Event RatesHui‐Chun Huang0Khoa N. Cao1Anne M. Ryschon2Kee‐Wong Phay3Tzung‐Dau Wang4Jan B. Pietzsch5Cardiovascular Center and Division of Cardiology Department of Internal Medicine National Taiwan University Hospital and National Taiwan University College of Medicine Taipei City TaiwanWing Tech Inc. Menlo Park California USAWing Tech Inc. Menlo Park California USAMedtronic Taiwan Ltd. Taipei City TaiwanCardiovascular Center and Division of Cardiology Department of Internal Medicine National Taiwan University Hospital and National Taiwan University College of Medicine Taipei City TaiwanWing Tech Inc. Menlo Park California USAABSTRACT Radiofrequency renal denervation (RF RDN) is recognized as an adjunct therapy for hypertension. This study evaluated the cost‐effectiveness of RF RDN for the Taiwanese healthcare system using results from the SPYRAL HTN‐ON MED randomized, sham‐controlled trial. A decision‐analytic Markov model projected clinical events, costs, and quality‐adjusted life‐years (QALYs) for RF RDN versus standard‐of‐care (SoC) in an Asian population context. Clinical event risk reductions from treatment effects on office‐based systolic blood pressure (oSBP) were derived from a meta‐regression study of 47 hypertension trials. SPYRAL HTN‐ON MED demographics and results (oSBP reduction of 4.9 mmHg against sham) were used in the base case analysis. The incremental cost‐effectiveness ratio (ICER) was assessed against a willingness‐to‐pay (WTP) threshold of three million Taiwan dollars (TWD) per QALY gained. Compared to SoC, RF RDN was projected to reduce clinical events, with relative risks of 0.80, 0.88, and 0.74 for stroke, myocardial infarction (MI), and heart failure (HF), respectively. The incremental costs and QALYs were 216 381 TWD and 0.25, respectively, resulting in an ICER of 850 932 TWD per QALY gained. The ICER was cost‐effective across a broad range of uncertainty analyses. Model‐based projections adjusted for East Asian event rates suggest RF RDN may significantly reduce events, making it a cost‐effective intervention in the Taiwanese healthcare system for treating uncontrolled hypertension.https://doi.org/10.1111/jch.70090cost‐effectiveness analysishypertensionrenal denervationTaiwan
spellingShingle Hui‐Chun Huang
Khoa N. Cao
Anne M. Ryschon
Kee‐Wong Phay
Tzung‐Dau Wang
Jan B. Pietzsch
Cost‐Effectiveness of Radiofrequency Renal Denervation in Taiwan Based on Clinical Evidence and Regional Event Rates
The Journal of Clinical Hypertension
cost‐effectiveness analysis
hypertension
renal denervation
Taiwan
title Cost‐Effectiveness of Radiofrequency Renal Denervation in Taiwan Based on Clinical Evidence and Regional Event Rates
title_full Cost‐Effectiveness of Radiofrequency Renal Denervation in Taiwan Based on Clinical Evidence and Regional Event Rates
title_fullStr Cost‐Effectiveness of Radiofrequency Renal Denervation in Taiwan Based on Clinical Evidence and Regional Event Rates
title_full_unstemmed Cost‐Effectiveness of Radiofrequency Renal Denervation in Taiwan Based on Clinical Evidence and Regional Event Rates
title_short Cost‐Effectiveness of Radiofrequency Renal Denervation in Taiwan Based on Clinical Evidence and Regional Event Rates
title_sort cost effectiveness of radiofrequency renal denervation in taiwan based on clinical evidence and regional event rates
topic cost‐effectiveness analysis
hypertension
renal denervation
Taiwan
url https://doi.org/10.1111/jch.70090
work_keys_str_mv AT huichunhuang costeffectivenessofradiofrequencyrenaldenervationintaiwanbasedonclinicalevidenceandregionaleventrates
AT khoancao costeffectivenessofradiofrequencyrenaldenervationintaiwanbasedonclinicalevidenceandregionaleventrates
AT annemryschon costeffectivenessofradiofrequencyrenaldenervationintaiwanbasedonclinicalevidenceandregionaleventrates
AT keewongphay costeffectivenessofradiofrequencyrenaldenervationintaiwanbasedonclinicalevidenceandregionaleventrates
AT tzungdauwang costeffectivenessofradiofrequencyrenaldenervationintaiwanbasedonclinicalevidenceandregionaleventrates
AT janbpietzsch costeffectivenessofradiofrequencyrenaldenervationintaiwanbasedonclinicalevidenceandregionaleventrates